27th March 2013 Sciformix Corporation, a world leading Scientific Process Organization (SPO), has announced its premium sponsorship of the 5th annual World Drug Safety Congress, taking place from April 24 - 25, 2013 at the Revere Hotel Boston Common, Boston, USA. The World Drug Safety Congress addresses strategic and crucial issues in the development and execution of drug safety programs. Senior executives of Sciformix, will be chairing the opening session and setting the stage on how organizations can stay on top of international regulatory requirements and streamline their drug safety programs.
Sciformix, premium sponsors of the event for the third year in a row, continues its success in its global delivery of services and solutions in Safety and Risk Management. Their scientific and safety experts work closely with the top global pharmaceutical and biopharmaceutical, generics, consumer product and medical devices organizations to support their safety needs throughout the entire product lifecycle. With substantial growth in business year on year, Sciformix is taking its position as a leader in drug safety services.
The World Drug Safety Congress aims to present innovative solutions to the key safety challenges facing both pharmaceutical industry and pharmacovigilance professionals worldwide. It brings together senior personnel from a range of global pharmaceutical companies, regulatory agencies and academic institutions to share their expertise in the drug safety arena. The conference provides an excellent opportunity for attendees to discuss diverse issues related to drug safety with specialists and practitioners. At the conference, Sciformix will be demonstrating its expertise by engaging with the speakers and delegates, sharing their knowledge of key developments in the global drug safety market, and demonstrating solutions that provide competitive advantage to participating companies.
Manish Soman, President and CEO comments "We are delighted to be a part of the World Drug Safety Congress. Our support of the event is part of our ongoing investment in the field of drug safety. We want to share the knowledge we have gained while working with clients over the years, which has been incorporated into our innovative methodology and approaches to the problems of drug safety and risk management".
To help drug safety professionals achieve excellence, world renowned expert Sidney Kahn, Senior Principal Pharmacovigilance Practice at Sciformix, will be addressing the audience with his keynote presentation on "The challenges in achieving excellence in the rapidly evolving global drug safety environment". On the second day of the conference, Chitra Lele, Chief Scientific Officer and co-founder at Sciformix will host an in-depth presentation and panellist discussion on "Taking the noise out of signal detection". Experts including Ram Tiwari, Ph.D., Associate Director, Office of Biostatistics, Center for Drug Evaluation & Research, US FDA and Michael Sprafka, Executive Director of Observation Research, Head of Pharmacovigilance-Epidemiology, Amgen, will provide practical solutions to the problems of inadequacies of available quantitative measures and indicate possible enhancements of the method during an informative and thought provoking presentation and panel discussion.
Sciformix partners with their clients through the entire drug development cycle, to provide a full range of services from study design to post marketing surveillance and commercialization support. Areas of specialization include Safety and Risk Management, Clinical Research & Post Approval Services, Medical Affairs, Scientific Writing and Regulatory Affairs.
Copies of presentations from Sciformix are available by emailing email@example.com. To learn more about Sciformix visit www.sciformix.com, email us at firstname.lastname@example.org, or call us at +1.877.576.5005.
Sciformix Corporation is a world leading Scientific Process Organization (SPO), providing scientific knowledge-based services to pharmaceutical and biopharmaceutical, generics, consumer products, medical devices and other healthcare companies - in the areas of Safety and Risk Management, Clinical Research & Post-Approval Services and Regulatory Affairs. Our mission is to partner with global life science companies to provide high quality scientific knowledge-based expertise that deliver better quality outcomes and improved efficiencies across the entire product lifecycle with the ultimate objective of improving quality of healthcare for patients worldwide. Corporate headquarters is located in Westborough, MA with operations in USA, India and the Philippines.
We create value for our clients through our singular focus on the life sciences industry, strong pharmaceutical domain competency, exceptional subject matter expertise, industry reputed scientific advisory board, uncompromising focus on quality, process rigor, predictable results, and ability to scale. Our portfolio of services spans the full spectrum of product lifecycle from pre-clinical and clinical to post marketing activities to help our customers solve complex analytical challenges, improve the quality of patient healthcare and increase client productivity.
Sciformix is dedicated to providing our clients outstanding services and solutions, fueled by an unrivaled commitment to quality. We share the same level of involvement, dedication and passion as our clients by becoming an integral part of their team. Our distinct combination of scientific expertise, process rigor and technology innovation delivers consistent, reliable and insightful results. Our ability to scale and grow to meet your evolving needs means we are flexible and dedicated to your success in delivering safe products with more efficiency and greater speed. We help you make the right decisions at the right time by providing Trusted Services Built on Science.
For further press information please contact: Gemma Clulow, The Scott Partnership: + 44 1477 539539 mail to email@example.com or Susan Najjar, Director of Marketing, Sciformix Corporation: + 1 617-264-0339 mail to firstname.lastname@example.org.